Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 6
2015 5
2016 7
2017 2
2018 1
2019 3
2020 2
2021 4
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK. Marx N, et al. Among authors: gollop nd. JAMA Cardiol. 2024 Feb 1;9(2):134-143. doi: 10.1001/jamacardio.2023.4602. JAMA Cardiol. 2024. PMID: 38170502 Free PMC article.
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
Filippatos G, Anker SD, Butler J, Farmakis D, Ferreira JP, Gollop ND, Brueckmann M, Iwata T, Pocock S, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Filippatos G, et al. Among authors: gollop nd. Eur J Heart Fail. 2022 Dec;24(12):2297-2304. doi: 10.1002/ejhf.2707. Epub 2022 Oct 24. Eur J Heart Fail. 2022. PMID: 36194680 Free PMC article.
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Böhm M, et al. Among authors: gollop nd. J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040. J Am Coll Cardiol. 2022. PMID: 35772911 Free article. Clinical Trial.
Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review.
Bergamasco A, Luyet-Déruaz A, Gollop ND, Moride Y, Qiao Q. Bergamasco A, et al. Among authors: gollop nd. Curr Heart Fail Rep. 2022 Jun;19(3):146-156. doi: 10.1007/s11897-022-00542-5. Epub 2022 Mar 30. Curr Heart Fail Rep. 2022. PMID: 35355204 Free PMC article. Review.
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V. Wanner C, et al. Among authors: gollop nd. Clin Kidney J. 2021 Jul 14;14(9):2136. doi: 10.1093/ckj/sfab104. eCollection 2021 Sep. Clin Kidney J. 2021. PMID: 34476096 Free PMC article.
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V; CARMELINA investigators. Wanner C, et al. Among authors: gollop nd. Clin Kidney J. 2021 Jan 17;14(1):226-236. doi: 10.1093/ckj/sfaa225. eCollection 2021 Jan. Clin Kidney J. 2021. PMID: 33564423 Free PMC article.
35 results